FDA advisers vote against US Singulair switch

6 May 2014 - Deborah Wilkes

Archived

Merck & Co's application to switch the asthma drug Singulair (montelukast) from prescription-to-OTC status as an allergy remedy has been rejected by advisers to the US Food and Drug Administration (FDA).

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: